Amgen stock is holding above $430, supported by its Dow Jones Industrial Average membership and a co

Elevation Point Wealth Partners LLC lifted its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 18.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 25,505 shares of the medical research company

Beutel Goodman & Co Ltd. lowered its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 19.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 520,577 shares of the medical research company

Commerce Bank lessened its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 1.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 256,448 shares of the medical research company

Bank of Nova Scotia cut its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 50.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 156,088 shares of the medical research company

Westpac Banking Corp raised its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 8.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,767 shares of the medical research company

Korea Investment CORP lessened its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 31.8% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 269,926 shares of the medical research company

EP Wealth Advisors LLC boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 46.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 70,291 shares of the medical research company

Emerald Investment Advisers LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 32.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,256 shares of the medical research company

Las acciones de Amgen cotizan cerca de máximos históricos después de unos sólidos resultados del segundo trimestre de 2026 y un precio pe de 2,52 dólares.

Bank of New York Mellon Corp decreased its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 2.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,695,586 shares of the medical research company

AssuredPartners Investment Advisors LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 191.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,651 shares of the medical research company

B. Metzler seel. Sohn & Co. AG lowered its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 10.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,041 shares of the medical research company

El gigante de la biotecnología Amgen Inc. llegó a un acuerdo para poner fin a una demanda colectiva propuesta que alegaba que una tarifa de 150 dólares al mes sobre los planes de salud de los empleados que consumían tabaco violaba la ley federal de beneficios, según un documento presentado el jueves ante un tribunal federal de California.

El gigante de la biotecnología Amgen Inc. llegó a un acuerdo para poner fin a una demanda colectiva propuesta que alegaba que una tarifa de 150 dólares al mes sobre los planes de salud de los empleados que consumían tabaco violaba la ley federal de beneficios, según un documento presentado el jueves ante un tribunal federal de California.

Las acciones de Amgen extienden su repunte de 2026 a medida que los inversores responden al crecimiento de ingresos de dos dígitos en el segundo trimestre

NewEdge Wealth LLC redujo su posición en acciones de Amgen Inc. (NASDAQ:AMGN - Free Report) en un 25,0% durante el segundo trimestre, según la compañía en su presentación 13F más reciente ante la SEC. La empresa poseía 110.074 acciones de la empresa de investigación médica.

Main Street Financial Solutions LLC compró una nueva participación en Amgen Inc. (NASDAQ:AMGN - Informe gratuito) en el segundo trimestre, según la compañía en su presentación 13F más reciente ante la Comisión de Bolsa y Valores. El inversor institucional compró 4.589 acciones de la compañía de investigación médica.

Wealthfront Advisers LLC redujo su posición en acciones de Amgen Inc. (NASDAQ:AMGN - Free Report) un 7,1% en el segundo trimestre, según su presentación 13F más reciente ante la Comisión de Bolsa y Valores. El inversor institucional poseía 84.152 acciones de la empresa de investigación médica